IGBA Statement for the World Health Organization’s Executive Board Meeting 154

The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking the learnings from the General Programme of Work 13 (GPW13) to the newly developed GPW14 to accelerate progress in global health.

Our industry remains committed to working collaboratively with stakeholders to reach SDG Target 3.8 on achieving Universal Healthcare Coverage (UHC) by enabling timely access to quality-assured, safe, cost-effective medicines for patients around the world. IGBA recognizes the many barriers that can prevent patients from accessing the medicines they need and underscores the importance of multisectoral efforts to overcome these challenges. We note that efforts to increase regulatory efficiency and improve sustainable procurement are of particular importance for the timely, reliable availability of generic and biosimilar medicines.

IGBA is pleased to join with private sector health partners to deliver a statement to the Executive Board on the importance of combating non-communicable diseases (NCDs) addressing these global drivers of morbidity and mortality and contributing to health improvements for people worldwide.

Recognizing the great impact to human health still posed by many infectious diseases, including tuberculosis, and the importance of timely and equitable availability of quality-assured, safe, and cost-effective medicines to address these diseases, IGBA welcomes the Executive Board’s discussion of the biannual report on the End TB strategy including progress on the implementation of the global strategy for tuberculosis research and innovation.

IGBA underscores the central role of the World Health Organization in progressing global health and notes the importance of the Executive Board’s budgetary and financial conversations. The role of the WHO in providing normative guidance, including for standardization of regulatory requirements, is central for the global convergence and harmonization of regulations related to medicines quality that is foundational for enabling equitable global access to medicines.

About IGBA

The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org.